Publications

Rickman DS, Beltran H, Demichelis F, Rubin MA.  2017.  Biology and evolution of poorly differentiated neuroendocrine tumors.. Nat Med. 23(6):1-10.

Lin P-C, Chiu Y-L, Banerjee S, Park K, Mosquera JMiguel, Giannopoulou E, Alves P, Tewari AK, Gerstein MB, Beltran H et al..  2013.  Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression.. Cancer Res. 73(3):1232-44.

Wilkes DC, Sailer V, Xue H, Cheng H, Collins CC, Gleave M, Wang Y, Demichelis F, Beltran H, Rubin MA et al..  2017.  A germline FANCA alteration that is associated with increased sensitivity to DNA damaging agents.. Cold Spring Harb Mol Case Stud. 3(5)

Demichelis F, Setlur SR, Banerjee S, Chakravarty D, Chen JYun Helen, Chen CX, Huang J, Beltran H, Oldridge DA, Kitabayashi N et al..  2012.  Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk.. Proc Natl Acad Sci U S A. 109(17):6686-91.

Robinson D, Van Allen EM, Wu Y-M, Schultz N, Lonigro RJ, Mosquera J-M, Montgomery B, Taplin M-E, Pritchard CC, Attard G et al..  2015.  Integrative clinical genomics of advanced prostate cancer.. Cell. 161(5):1215-28.

Armenia J, Wankowicz SAM, Liu D, Gao J, Kundra R, Reznik E, Chatila WK, Chakravarty D, G Han C, Coleman I et al..  2018.  The long tail of oncogenic drivers in prostate cancer.. Nat Genet. 50(5):645-651.

Collins CC, Volik SV, Lapuk AV, Wang Y, Gout PW, Wu C, Xue H, Cheng H, Haegert A, Bell RH et al..  2012.  Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target.. Mol Cancer Ther. 11(3):775-83.

Pisapia DJ, Salvatore S, Pauli C, Hissong E, Eng K, Prandi D, Sailer V-W, Robinson BD, Park K, Cyrta J et al..  2017.  Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models.. JCO Precis Oncol. 2017

Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, Hess J, Sigouros M, Donoghue A, Kossai M et al..  2018.  Patient derived organoids to model rare prostate cancer phenotypes.. Nat Commun. 9(1):2404.

Pauli C, Hopkins BD, Prandi D, Shaw R, Fedrizzi T, Sboner A, Sailer V, Augello M, Puca L, Rosati R et al..  2017.  Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine.. Cancer Discov.

Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J et al..  2018.  A phase II trial of the aurora kinase A inhibitor alisertib for patients with castration resistant and neuroendocrine prostate cancer: efficacy and biomarkers.. Clin Cancer Res.

Beltran H, Demichelis F.  2015.  Prostate cancer: Intrapatient heterogeneity in prostate cancer.. Nat Rev Urol. 12(8):430-1.

Baca SC, Prandi D, Lawrence MS, Mosquera JMiguel, Romanel A, Drier Y, Park K, Kitabayashi N, MacDonald TY, Ghandi M et al..  2013.  Punctuated evolution of prostate cancer genomes.. Cell. 153(3):666-77.

Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen C-C, Wongvipat J, Ku S-Y, Gao D, Cao Z et al..  2017.  SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.. Science. 355(6320):84-88.

Prandi D, Baca SC, Romanel A, Barbieri CE, Mosquera J-M, Fontugne J, Beltran H, Sboner A, Garraway LA, Rubin MA et al..  2014.  Unraveling the clonal hierarchy of somatic genomic aberrations.. Genome Biol. 15(8):439.

Beltran H, Eng K, Mosquera JMiguel, Sigaras A, Romanel A, Rennert H, Kossai M, Pauli C, Faltas B, Fontugne J et al..  2015.  Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.. JAMA Oncol. 1(4):466-74.